AB Science SA

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

07 May 2024 11:05:45 By Nasdaq GlobeNewswire

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

02 May 2024 12:14:41 By Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2023 annual financial report

30 Apr 2024 11:56:04 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

03 Apr 2024 11:08:55 By Nasdaq GlobeNewswire

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

13 Mar 2024 06:58:59 By Nasdaq GlobeNewswire

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

07 Mar 2024 08:20:57 By Nasdaq GlobeNewswire

AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

06 Mar 2024 13:21:09 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

01 Mar 2024 11:07:34 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29 Feb 2024 04:49:23 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26 Feb 2024 11:32:14 By Nasdaq GlobeNewswire

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

26 Jan 2024 11:01:21 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

15 Jan 2024 11:06:57 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

28 Nov 2023 12:22:40 By Nasdaq GlobeNewswire

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

27 Nov 2023 01:04:30 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

29 Sep 2023 12:49:30 By Nasdaq GlobeNewswire

AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18 Sep 2023 11:05:35 By Nasdaq GlobeNewswire

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

26 Jun 2023 11:11:42 By Nasdaq GlobeNewswire

AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

01 Jun 2023 11:01:02 By Nasdaq GlobeNewswire

AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

17 May 2023 13:14:57 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

09 May 2023 11:06:29 By Nasdaq GlobeNewswire